# CD19-redirected Autologous Cells (CAR-CD19 T Cells)

> **NCT02933775** · PHASE1 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 45 (estimated)

## Conditions studied

- CD19 Positive Malignant B-cell Leukemia and Lymphoma

## Interventions

- **GENETIC:** CAR-CD19 T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02933775
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-04
- **Final completion:** 2020-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2016-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02933775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02933775, "CD19-redirected Autologous Cells (CAR-CD19 T Cells)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02933775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*